Resverlogix Commences Phase 2 Atherosclerosis Clinical Trial

Cleveland Clinic Initiates Dosing in ASSERT Trial

CALGARY, Canada, December 22 - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced
today that it has begun dosing patients in its
US Phase 2 clinical trial lead by Cleveland Clinic. This trial will examine
RVX-208, Resverlogix's oral small molecule therapy for the treatment of
atherosclerosis, in patients with stable coronary artery disease (CAD). This
study is chaired by Dr. Steven Nissen, MD, Chairman of the Cleveland Clinic
Department of Cardiovascular Medicine and the principal investigator is Dr.
Stephen Nicholls, Medical Director of Intravascular Ultrasound at Cleveland
Clinic. The Cleveland Clinic has named this trial, ASSERT, which stands for
ApoA1 Synthesis Stimulation Evaluation in Patients Requiring Treatment for
Coronary Artery Disease. A total of 40 investigator sites across the US will
be participating in the study.

"I am pleased to see the start of this 18 week randomized, outpatient
multicenter, double-blind, placebo-controlled study that will administer
RVX-208 to approximately 280 patients with stable CAD for 13 weeks," said Dr.
Stephen J. Nicholls, MBBS, PhD, Medical Director of the Atherosclerosis
Imaging Core Laboratories at Cleveland Clinic and Cardiovascular Director of
the Cleveland Clinic Coordinating Center for Clinical Research. "This trial
is one of two parallel studies, in this particular study the focus is on
stable CAD patients, while the second trial will be focused on unstable
acute coronary syndrome and will include the use of intravascular ultrasound
(IVUS)."

Cardiovascular disease is the leading cause of death in the US and other
developed nations costing the American health care system an estimated $448.5
billion in 2008. A key underlying cause of cardiovascular disease is
atherosclerosis, a build-up of plaque in the arteries often referred to as
'hardening of the arteries'.

The primary objective of this study is to determine if RVX-208 will
produce an increase in plasma ApoA-l levels compared to placebo group after
three months of dosing. The secondary objectives are to examine the safety
and tolerability of RVX-208, to compare the dose and time response
relationships for ApoA-l over time as well as to examine and key reverse
cholesterol makers such as Alpha 1 HDL.

"The initiation of the ASSERT Trial is another important milestone that
Resverlogix has achieved this year. Our clinical trials to date have produced
very encouraging results for our lead drug, RVX-208, for the treatment of
atherosclerosis. Currently, there is a void in therapies that can regress
atherosclerosis. The current standard of care is statin therapies, which can
only stop atherosclerosis from progressing but in almost all cases is unable
to remove it. If RVX-208 is able to achieve this goal it would be an
important step toward the reduction of disease risk and lower health system
costs. We are delighted to have this trial dose its first patients two
months ahead of schedule," said Donald J. McCaffrey, President and CEO of
Resverlogix.

About RVX-208

RVX-208, a novel small molecule therapeutic that facilitates endogenous
ApoA-I production, is positioned to be one of the most promising emerging
drugs in the treatment of atherosclerosis. To the Company's knowledge RVX-208
is the only novel small molecule that is specifically designed to increase
ApoA-I production and thereby raise HDL levels thus enhancing HDL
functionality to augment reverse cholesterol transport (RCT). RCT is a
pathway by which accumulated cholesterol is transported from the arterial
wall to the liver for excretion, thus preventing atherosclerosis.

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in the
development of novel therapies for important global medical markets with
significant unmet medical needs. The NexVas(TM) PR program is the Company's
primary focus which is to develop novel small molecules that enhance ApoA-I.
These vital therapies address the burden of atherosclerosis and other
important diseases such as Acute Coronary Syndrome, Diabetes, Alzheimer's
disease, Peripheral Artery Disease and other vascular disorders. Resverlogix
Corp. trades on the Toronto Stock Exchange (TSX:RVX). For further information
please visit www.resverlogix.com.

This news release may contain certain forward-looking statements as
defined under applicable Canadian securities legislation, including our
statements with respect to vision to be a leader in the research, development
and commercialization of novel therapeutics that reduce the risk of
cardiovascular disease including atherosclerosis, diabetes, Alzheimer's
disease, Peripheral Artery Disease and other vascular diseases. These
forward-looking statements contained herein that are not based on historical
fact, including without limitation statements containing the words
"believes", "anticipates", "plans", "intends", "will", "should", "expects",
"continue", "estimate", "forecasts" and other similar expressions. Our
actual results, events or developments could be materially different from
those expressed or implied by these forward-looking statements. We can give
no assurance that any of the events or expectations will occur or be
realized. By their nature, forward-looking statements are subject to
numerous known and unknown risks and uncertainties including
but not limited to those associated with the success
of research and development programs, clinical trial programs including
possible delays in patient recruitment, the regulatory approval process,
competition, securing and maintaining corporate alliances, market acceptance
of the Company's products, the availability of government and insurance
reimbursements for the Company's products, the strength of intellectual
property, financing capability, the potential dilutive effects of any
financing, reliance on subcontractors and key personnel and additional risk
factors discussed in other documents we file from time to time with
securities authorities, which are available through SEDAR at
www.sedar.com. Additionally, risks and uncertainties are discussed
in detail in the December 15, 2009 MD&A. The forward-looking statements
contained in this news release are expressly qualified by this
cautionary statement are made as of the date hereof. The Company
disclaims any intention and has no obligation or responsibility,
except as required by law, to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise. The TSX Exchange does not accept responsibility for the
adequacy or accuracy of this news release.

For further information: Theresa Kennedy, VP, Corporate Communications,
Resverlogix Corp., Phone: +1-(403)254-9252, Fax: +1-(403)-256-8495, Email:
Theresa@resverlogix.com; Sarah Zapotichny, Manager, Investor Relations,
Resverlogix Corp., Phone: +1-(403)-254-9252, Fax: +1-(403)-256-8495, Email:
Sarah@resverlogix.com; US Investor Relations, Susan Noonan, Managing
Partner, S.A. Noonan Communications, LLC, Phone: +1-(212)-966-3650, Email:
susan@sanoonan.com; US Media Relations, Eric Goldman, Vice President, Rx
Communications Group, Phone: +1-(917)-322-2563, Email: egoldman@rxir.com

For further information: Theresa Kennedy, VP, Corporate Communications, Resverlogix Corp., Phone: +1-(403)254-9252, Fax: +1-(403)-256-8495, Email: Theresa at resverlogix.com; Sarah Zapotichny, Manager, Investor Relations, Resverlogix Corp., Phone: +1-(403)-254-9252, Fax: +1-(403)-256-8495, Email: Sarah at resverlogix.com; US Investor Relations, Susan Noonan, Managing Partner, S.A. Noonan Communications, LLC, Phone: +1-(212)-966-3650, Email:
susan at sanoonan.com; US Media Relations, Eric Goldman, Vice President, Rx Communications Group, Phone: +1-(917)-322-2563, Email: egoldman at rxir.com